StreetInsider.com News Articles

RBC Capital on Neurocrine Bio. (NBIX): 'We like the setup and remain buyers'

Tue, 08 Sep 2026 09:15:53 -0400

RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $198.00 price target on Neurocrine Bio. (NASDAQ: NBIX).

The analyst commented: "Getting Ahead of a Catalyst-Rich 2027 - Before a Potential Run-Up; Following the recent pullback, NBIX now trades at a ~$16B cap, <4x our durable annual Ingrezza+Crenessity sales est. - implying minimal embedded value for Vykat or the pipeline. We expect strong Ingrezza +Crenessity numbers to drive 2H26 appreciation, with any improved Vykat performance further catalyzing upside - but also see potential for shares to run up into the higher density of '27 pipeline catalysts. While data from the

Neurocrine Bio. (NBIX) PT Raised to $253 at Citi

Thu, 03 Sep 2026 05:02:18 -0400

Citi analyst Yigel Nochomovitz raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $253.00 (from $249.00) while maintaining a Buy rating.

Neurocrine Bio. (NBIX) PT Lowered to $182 at Morgan Stanley

Thu, 13 Aug 2026 08:09:11 -0400

Morgan Stanley analyst Jeffrey Hung lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $182.00 (from $196.00) while maintaining a Equalweight rating.

Neurocrine's Ingrezza study shows quality-of-life gains in TD patients

Wed, 12 Aug 2026 08:30:55 -0400

Neurocrine Biosciences (NASDAQ: NBIX) announced the publication of results from its KINECT-PRO Phase 4 open-label study, showing that once-daily Ingrezza (valbenazine) capsules produced improvements in patient-reported quality of life and daily functioning among people with tardive dyskinesia (TD). The findings were published in CNS Spectrums.

The study enrolled 59 patients who received Ingrezza at doses of 40 mg, 60 mg, or 80 mg once daily for up to 24 weeks. Fifty-two patients completed the Week 24 visit, with 45 included in efficacy analyses. At baseline, approximately 41% of patients had mild TD movement severity, while 59% had moderate or severe TD.

Mean

Neurocrine's Ingrezza study shows quality-of-life gains in TD patients

Wed, 12 Aug 2026 08:30:55 -0400

Mean

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living

Wed, 12 Aug 2026 08:30:00 -0400

INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia across multiple validated patient-reported outcomes
Mean improvements in the patient-reported impacts of tardive dyskinesia and clinician-rated movement severity exceeded established thresholds for clinically meaningful change at Week 24, with improvements observed regardless of underlying psychiatric diagnosis or baseline movement severity
Approximately 58% of patients met the threshold for tardive dyskinesia symptomatic remission at Week 24, based on clinician assessment of movement severity
Findings reinforce that even patients with mild tardive dyskinesia movements are impacted and

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living

Wed, 12 Aug 2026 08:30:00 -0400

INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia across multiple validated patient-reported outcomes
Mean improvements in the patient-reported impacts of tardive dyskinesia and clinician-rated movement severity exceeded established thresholds for clinically meaningful change at Week 24, with improvements observed regardless of underlying psychiatric diagnosis or baseline movement severity
Approximately 58% of patients met the threshold for tardive dyskinesia symptomatic remission at Week 24, based on clinician assessment of movement severity
Findings reinforce that even patients with mild tardive dyskinesia movements are impacted and

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living

Wed, 12 Aug 2026 08:30:00 -0400

INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia across multiple validated patient-reported outcomes
Mean improvements in the patient-reported impacts of tardive dyskinesia and clinician-rated movement severity exceeded established thresholds for clinically meaningful change at Week 24, with improvements observed regardless of underlying psychiatric diagnosis or baseline movement severity
Approximately 58% of patients met the threshold for tardive dyskinesia symptomatic remission at Week 24, based on clinician assessment of movement severity
Findings reinforce that even patients with mild tardive dyskinesia movements are impacted and

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living

Wed, 12 Aug 2026 08:30:00 -0400

INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia across multiple validated patient-reported outcomes
Mean improvements in the patient-reported impacts of tardive dyskinesia and clinician-rated movement severity exceeded established thresholds for clinically meaningful change at Week 24, with improvements observed regardless of underlying psychiatric diagnosis or baseline movement severity
Approximately 58% of patients met the threshold for tardive dyskinesia symptomatic remission at Week 24, based on clinician assessment of movement severity
Findings reinforce that even patients with mild tardive dyskinesia movements are impacted and

Neurocrine starts Phase 1 trial of obesity drug NBIP-1968

Fri, 07 Aug 2026 08:30:24 -0400

Neurocrine Biosciences (NASDAQ: NBIX) has initiated a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a treatment for obesity, according to a company statement.

The study will initially assess single ascending doses of NBIP-1968 in adult participants across a range of body mass index categories, including overweight and obese individuals.

NBIP-1968 is an internally discovered, investigational long-acting compound designed for once-weekly subcutaneous administration. It targets receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon, with the goal of influencing metabolic pathways involved in appetite regulation, energy balance,

Neurocrine starts Phase 1 trial of obesity drug NBIP-1968

Fri, 07 Aug 2026 08:30:24 -0400

The study will initially assess single ascending doses of NBIP-1968 in adult participants across a range of body mass index categories, including overweight and obese individuals.

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

Fri, 07 Aug 2026 08:30:00 -0400

Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and investigational metabolic disease pipeline

SAN DIEGO, Aug. 7, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity.

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

Fri, 07 Aug 2026 08:30:00 -0400

Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and investigational metabolic disease pipeline

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

Fri, 07 Aug 2026 08:30:00 -0400

Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and investigational metabolic disease pipeline

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

Fri, 07 Aug 2026 08:30:00 -0400

Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and investigational metabolic disease pipeline

Form 4 NEUROCRINE BIOSCIENCES For: Aug 04 Filed by: Onyia Jude

Wed, 05 Aug 2026 17:36:00 -0400

si-local-file:///var/storage/secattach/20260805/26876168.html

Form 4 NEUROCRINE BIOSCIENCES For: Aug 04 Filed by: Onyia Jude

Wed, 05 Aug 2026 17:36:00 -0400

si-local-file:///var/storage/secattach/20260805/26876168.html

Neurocrine Bio. (NBIX) PT Raised to $213 at Truist Securities

Mon, 03 Aug 2026 07:06:06 -0400

Truist Securities analyst Danielle Brill raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $213.00 (from $200.00) while maintaining a Buy rating.

H.C. Wainwright Reiterates Buy Rating on Neurocrine Bio. (NBIX)

Mon, 03 Aug 2026 06:54:57 -0400

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $215.00 price target on Neurocrine Bio. (NASDAQ: NBIX).

The analyst commented: "Neurocrine reaffirmed 2H27 Phase 3 topline for both osavampator in major depressive disorder and the first direclidine study in schizophrenia, with a second schizophrenia Phase 3 in 2028, which we think are the two big binary catalysts that have the potential to change the course of the company. Note that direclidine (NBI-'568) is a selective M4 orthosteric agonist that in Phase 2 produced a 7.5-point placebo-adjusted PANSS improvement at 20 mg once daily, an effect size of 0.61, with GI

Neurocrine Bio. (NBIX) PT Raised to $210 at Canaccord

Mon, 03 Aug 2026 06:44:05 -0400

(Updated - August 3, 2026 6:44 AM EDT)

Canaccord analyst Sumant Kulkarni raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $210.00 (from $200.00) while maintaining a Buy rating.

The analyst commented: "NBIX reported its 2Q26 results after the close yesterday (7/30). Sales of Ingrezza (valbenazine for tardive dyskinesia/TD, Huntington's chorea)/Crenessity (crinecerfont for classic congenital adrenal) came in at $716mn/ $184mn, which blew past our $675mn/$146mn and consensus of $688mn/$169mn. This was the first quarter including the recent acquisition of Soleno, and Vykat XR (diazoxide choline extended release) for hyperphagia (excessive appetite) in Prader-Willi syndrome (PWS) had partial quarter sales of

Neurocrine Bio. (NBIX) PT Raised to $210 at Canaccord

Mon, 03 Aug 2026 06:44:05 -0400

(Updated - August 3, 2026 6:44 AM EDT)

Canaccord analyst Sumant Kulkarni raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $210.00 (from $200.00) while maintaining a Buy rating.

Form S-8 NEUROCRINE BIOSCIENCES

Fri, 31 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260731/26850835.html

Form S-8 NEUROCRINE BIOSCIENCES

Fri, 31 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260731/26850835.html

Form 8-K/A NEUROCRINE BIOSCIENCES For: May 14

Fri, 31 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260731/26850615.html

Form 8-K/A NEUROCRINE BIOSCIENCES For: May 14

Fri, 31 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260731/26850615.html